Immune checkpoint inhibitors efficacy in cervical cancer
Download as PDF
To explore the clinical effects of immune checkpoint inhibitors in the treatment of cervical cancer patients. [Methods] A total of 218 patients with cervical cancer admitted to our hospital were included. It is administered according to the clinical treatment plan of immunotherapy, including single administration such as Nivolumab and Ipilimumab and combined administration with chemotherapy. [Results] The effective rate of treatment was 78%; after treatment, the positive rate of vaginal resection margin was 4.00%, the positive rate of lymph node metastasis was 3.00%, the positive rate of parauterine involvement was 6.00%, and the positive rate of vascular infiltration was 2.00%; After treatment, the tumor size was significantly reduced. The maximum diameter of the tumor before treatment is 5.24 cm, and the maximum diameter of the tumor after treatment is 3.06 cm; After immune checkpoint inhibitor treatment ,the 1, 2 and 3 year tumor-free survival rates were 93.50%, 83.42%, and 79.63%, respectively, the median progression-free survival was 35.4 months, and the median overall survival was 78.2 months. The adverse reaction rate is low and the adverse reactions are mainly minor reactions. Three patients had grade III reactions. [Conclusion] Immune checkpoint inhibitors have relatively satisfactory clinical effects for patients with cervical cancer. They can significantly shorten the maximum tumor diameter, enhance the therapeutic effect and reduce the incidence of pathological positives, and are worthy of clinical application.
Immune checkpoint inhibitors, immunotherapy, cervical cancer